NCT00150072已完成2 期
Phase II Study of Imatinib Mesylate in Chordoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 1
- 主要终点
- Tumor response
研究概览
简要总结
Preliminary response data, observed by Casali (Cancer, 2004) with imatinib 800 mg/day in patients affected by chordoma, need to be confirmed by a Phase II study, whose primary endpoint will be the formal assessment of clinical and pathological response. Aim of the study will be to explore treatment's activity, but also the potential impact of tumor response, the feasibility and outcome of subsequent surgery and radiotherapy. In addition, patterns of tumour response need to be investigated as well, given the peculiar patterns of response shown with molecular-targeted therapy in solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological diagnosis of chordoma.
- •Biomolecular or immunohistochemical evidence of Imatinib mesylate target (PDGFRβ activation and/or presence of PDGFB). Biomolecular assessment of PDGFRβ activation should be made whenever possible. To this end, if frozen material is not available, obtaining of, fresh material is encouraged, if it should be obtained with no major distress for the patient, preferably through an incisional biopsy (to allow immunoprecipitation) or, if this is not feasible, a Trucut biopsy (to allow Western Blot assessment). However, if frozen or fresh material cannot be obtained, paraffined material is also acceptable.
- •The biomolecular assessment will be centralized to the reference centers (to be defined).
- •Measurable or evaluable disease
- •Surgical resection of local disease unfeasible radically, or unaccepted by the patient, or amenable to become less demolitive, or easier, or likely more feasible, after cytoreduction, and/or metastatic disease. Debulking surgery before enrolment is allowed. In this case, enrolment should occur at least one month after surgery
- •Performance status 0, 1, 2 or 3 (ECOG) (see § 8.1).
- •Adequate end organ function, defined as the following: total bilirubin <1.5 x ULN, SGOT and SGPT <2.5 x UNL (or <5 x ULN if hepatic metastases are present), creatinine <1.5 x ULN.
- •Adequate bone marrow function, defined as the following: ANC >1.5 x 10^9/L, platelets >100 x 10^9/L, Hb >9 g/dL. Blood transfusions are allowed to reach the baseline requested Hb level.
- •Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
- •Written, voluntary, informed consent.
排除标准
- •Previous treatment with any other investigational or not investigational agents within 28 days of first day of study drug dosing.
- •Other primary malignancy with <5 years clinically assessed disease-free interval, except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged to entail a low risk of relapse.
- •Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e., congestive heart failure, myocardial infarction within 6 months of study)
- •Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
- •Known brain metastasis.
- •Known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
- •Known diagnosis of human immunodeficiency virus (HIV) infection.
- •Previous radiotherapy to >=25 % of the bone marrow.
- •Major surgery within 2 weeks prior to study entry.
- •Expected non-compliance to medical regimens.
研究组 & 干预措施
imatinib
Experimental
干预措施: imatinib (Drug)
结局指标
主要结局
Tumor response
时间窗: Every 3 months for 2 years
objective response according to RECIST and clinical response
次要结局
- Progression free survival(2 years)
- Safety and tolerability(2 years)
- Overall survival(2 years)
- proportion of patients undergoing complete surgery(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or MeningiomaBrain and Central Nervous System TumorsNCT00010049Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins105
已完成
2 期
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryAcral Lentiginous Malignant MelanomaRecurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV MelanomaNCT00470470National Cancer Institute (NCI)30
已完成
2 期
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)Gastrointestinal Stromal TumorsNCT00237172Novartis Pharmaceuticals72
已完成
2 期
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansDermatofibrosarcoma ProtuberansAdult FibrosarcomaRecurrent Adult Soft Tissue SarcomaStage IV Adult Soft Tissue SarcomaNCT00084630National Cancer Institute (NCI)40
进行中（未招募）
不适用
PHASE II STUDY OF IMATINIB MESYLATEIN CHORDOMATreatment of advanced or unresectable chordomaMedDRA version: 6.1Level: PTClassification code 10008747EUCTR2004-001362-40-ITOVARTIS FARMA